Literature DB >> 6824923

Paradoxical reinforcing properties of apomorphine: effects of nucleus accumbens and area postrema lesions.

D van der Kooy, N R Swerdlow, G F Koob.   

Abstract

Apomorphine (0.01-10.0 mg/kg, subcutaneously) paradoxically produced both dose-dependent aversive and positive reinforcing effects, as measured in conditioned taste aversion and place preference paradigms, respectively. The conditioned taste aversions produced by apomorphine were not modified in rats with bilateral 6-hydroxydopamine (6-OHDA) lesions of the nucleus accumbens (producing 92% depletion of dopamine in the nucleus accumbens) nor in rats with thermal lesions of the area postrema. Both types of lesions were behaviorally verified as effective in other paradigms; the 6-OHDA lesions potentiated the facilitatory effects to a novel flavor paired with scopolamine methylnitrate (1.0 mg/kg, intraperitoneally). However, 6-OHDA lesions of the nucleus accumbens did clearly potentiate the conditioned place preferences induced by apomorphine. These results suggest that both the positive reinforcing and locomotor effects of apomorphine may partially result from activation of post-synaptic dopamine receptors in the nucleus accumbens. Moreover, the dissociation of apomorphine's aversive and positive reinforcing properties revealed by the 6-OHDA lesions may provide the first step in attempts to pinpoint the different brain sites of action where apomorphine produces its opposite motivational effects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6824923     DOI: 10.1016/0006-8993(83)91071-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  12 in total

1.  Place conditioning with dopamine D1 and D2 agonists injected peripherally or into nucleus accumbens.

Authors:  N M White; M G Packard; N Hiroi
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 2.  Dopamine and addiction: what have we learned from 40 years of research.

Authors:  Marcello Solinas; Pauline Belujon; Pierre Olivier Fernagut; Mohamed Jaber; Nathalie Thiriet
Journal:  J Neural Transm (Vienna)       Date:  2018-12-19       Impact factor: 3.575

3.  Area postrema lesions attenuate LiCl-induced c-Fos expression correlated with conditioned taste aversion learning.

Authors:  Corinne M Spencer; Lisa A Eckel; Rahel Nardos; Thomas A Houpt
Journal:  Physiol Behav       Date:  2011-08-24

4.  Independence of amphetamine reward from locomotor stimulation demonstrated by conditioned place preference.

Authors:  G D Carr; A G Phillips; H C Fibiger
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

5.  Subsensitivity to rewarding and locomotor stimulant effects of a dopamine agonist following chronic mild stress.

Authors:  M Papp; R Muscat; P Willner
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Restrained rats learn amphetamine-conditioned locomotion, but not place preference.

Authors:  N R Swerdlow; G F Koob
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

7.  Pramipexole induced place preference after L-dopa therapy and nigral dopaminergic loss: linking behavior to transcriptional modifications.

Authors:  Simon Loiodice; Poppy Winlow; Sarah Dremier; Etienne Hanon; David Dardou; Omar Ouachikh; Aziz Hafidi; Andre Nogueira da Costa; Franck Durif
Journal:  Psychopharmacology (Berl)       Date:  2016-09-10       Impact factor: 4.530

8.  Yoked delivery of cocaine is aversive and protects against the motivation for drug in rats.

Authors:  Robert C Twining; Matthew Bolan; Patricia S Grigson
Journal:  Behav Neurosci       Date:  2009-08       Impact factor: 1.912

9.  Glucocorticoids attenuate taste aversions produced by toxins in rats.

Authors:  S Revusky; G M Martin
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 10.  Do conditioned taste aversions result from activation of emetic mechanisms?

Authors:  V L Grant
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.